

MVIC Symposium 2024 – Program

Date	Wednesday the 16 th of October to Thursday the 17 th of October 2024
Time	Day 1: 08:30-17:40, Day 2: 08:30-13:00
Venue	Auditorium in building Inspira, Medicon Village, Lund, Sweden

Day 1 – Wednesday 16 October 2024

08:30-09:00	Symposium registration	
09:00-09:15	Welcome to MVIC Symposium 2024	<i>Lars Asking, MVIC</i>

Plenary

Chairman: Lars Asking

09:15-09:55	Current and future inhalation landscape - diseases, molecules/modalities and new players	<i>Dr. Gunilla Petersson, Inhaled Delivery Consulting</i>
09:55-10:15	Advantages and limitations of customizable nebulizer platform for combination product development	<i>Henry Cuevas Brun, HCmed Innovations</i>

10:15-11:00 Coffee and mingle

Regulatory science and novel approaches

Chairman: Dr. Per Bäckman

11:00-11:30	The inhaled Biopharmaceutical Classification System – Enablement and potential product development and regulatory insights	<i>Dr. Jayne Hastedt, JDP Pharma</i>
11:30-12:00	Optimizing inhaled drug development through in silico trials	<i>Dr. Maximilian Grill, Ebenbuild</i>
12:00-12:30	Human PK studies with PreciseInhale – regional lung targeting assessment	<i>Ass. Prof. Per Gerde, Inhalation Sciences</i>

12:30-13:45 Lunch and mingle

Regulatory science and novel approaches cont.

Chairman: Dr. Per Bäckman

13:45-14:15	New guidelines for Inhaled Generic Medicines - implications for the industry	<i>Dr. Mikael Ekström, Iconovo</i>
-------------	--	------------------------------------

Pharmaceutics

Chairman: Adj. Prof. Kyrre Thalberg

14:15-14:35	<i>In vitro</i> – <i>in vivo</i> correlation of levodopa dry powder for inhalation	<i>Dr. Julia Berends, Univ. of Groningen</i>
14:35-14:55	Biologics dosing by Dry-powder inhalers	<i>Dr. Jaap Wieling, PureIMS</i>

MVIC AB

Postal address:
Medicon Village, The Spark
SE-223 81 Lund, Sweden

E-mail: info@mvic.se
www.mvic.se

Org. no: 556929-8820
VAT no: SE556929882001

14:55-16:05 Coffee and mingle**Pharmaceutics cont.***Chairman: Adj. Prof. Kyrre Thalberg*

16:05-16:35	Next generation of propellants for pMDIs	<i>Dr. Kellisa Lachacz, AstraZeneca</i>
16:35-17:05	The role of mechanical properties in DPI carriers - an overlooked subject	<i>Zeredescht Majid, Kiel University</i>
17:05-17:35	Possibilities using TOF-SIMS in inhaled drug delivery	<i>Dr. Peter Sjövall, RISE</i>
17:35-17:40	Close and summary	<i>Lars Asking, MVIC</i>

17:45-18:30 Drinks reception**18:30- Symposium dinner****Day 2 – Thursday 17 October 2024****Opportunities in inhaled drug delivery***Chairman: Dr. Karin von Wachenfeldt*

08:30-09:00	Ambition Zero Carbon: CFD-PBBM towards alternative bioequivalence studies for inhalation aerosols with Next Generation Propellant	<i>Dr. Duy Nguyen, AstraZeneca</i>
09:00-09:30	Inhalation toxicology of biologics	<i>Dr. Joshua Gregory, Affibody</i>
09:30-09:50	Intranasal Powder: Process, Formulation and Pre-clinical Characterization	<i>Dr. Jonas Sävmarker, Orexo</i>

09:50-10:50 Coffee and mingle**Opportunities in inhaled drug delivery cont.***Chairman: Ass. Prof. Oskar Hallgren*

10:50-11:20	Inhaled non-small molecules: Opportunities for innovation and the need for foundational research in inhalation science	<i>Dr. Markus Fridén, AstraZeneca</i>
11:20-11:50	Nonclinical development of inhaled biopharmaceuticals, oligonucleotides and gene therapies	<i>Dr. Bruce Hamilton, Labcorp</i>
11:50-12:00	Closing symposium	<i>Lars Asking, MVIC</i>

12:00-13:00 Lunch and mingle**MVIC AB**Postal address:
Medicon Village, The Spark
SE-223 81 Lund, SwedenE-mail: info@mVIC.se
www.mVIC.seOrg. no: 556929-8820
VAT no: SE556929882001